Please visit answersincme.com/BCJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology discusses JAK inhibitor therapy for patients with myelofibrosis. Upon completion of this activity, participants should be better able to: Identify early signs of ruxolitinib failure for timely risk stratification of patients with myelofibrosis (MF); Describe the clinical profiles of novel JAK inhibitors for the treatment of patients with MF; and Outline evidence-based strategies to optimize JAK inhibitor therapy for patients with MF.